CIK 0001781983 · Non-accelerated filer<br>Smaller reporting company
Aprea Therapeutics, Inc.
Sign in to watch- Ticker
- APRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 215-948-4119
- Business address
- 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 52 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-10 | Attar Eyal C. SVP, Chief Medical Officer | Grant or award | +42,900 | 89,900 | ||
| 2022-03-10 | Attar Eyal C. SVP, Chief Medical Officer | Grant or award · Stock Option (right to Buy) | +185,900 | 185,900 | ||
| 2022-03-10 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Grant or award | +24,700 | 43,700 | ||
| 2022-03-10 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Grant or award · Stock Option (right to Buy) | +100,000 | 100,000 | ||
| 2022-02-28 | Attar Eyal C. SVP, Chief Medical Officer | Sale | −36,000 | $1.73 | $62K | 47,000 |
| 2022-02-25 | SCHADE CHRISTIAN S Chairman & CEO | Shares withheld for taxes | −21,644 | $1.74 | $38K | 155,016 |
| 2022-02-25 | Korbel Gregory Alan SVP, Chief Business Officer | Shares withheld for taxes | −1,326 | $1.74 | $2K | 15,841 |
| 2022-02-25 | Coiante Scott M SVP, Chief Financial Officer | Shares withheld for taxes | −14,817 | $1.74 | $26K | 76,649 |
| 2021-12-01 | Korbel Gregory Alan SVP, Chief Business Officer | Option exercise | +27,500 | $0.92 | $25K | 44,667 |
| 2021-12-01 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $3.96 | $109K | 17,167 |
| 2021-12-01 | Korbel Gregory Alan SVP, Chief Business Officer | Option exercise · Stock Option (right to Buy) | −27,500 | 2,335 | ||
| 2021-11-01 | Korbel Gregory Alan SVP, Chief Business Officer | Option exercise | +27,500 | $0.92 | $25K | 44,667 |
| 2021-11-01 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $5.00 | $138K | 17,167 |
| 2021-11-01 | Korbel Gregory Alan SVP, Chief Business Officer | Option exercise · Stock Option (right to Buy) | −25,245 | 0 | ||
| 2021-11-01 | Korbel Gregory Alan SVP, Chief Business Officer | Option exercise · Stock Option (right to Buy) | −2,255 | 29,835 | ||
| 2021-10-01 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Option exercise | +50,000 | $0.92 | $46K | 69,000 |
| 2021-10-01 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Sale | −50,000 | $4.89 | $245K | 19,000 |
| 2021-10-01 | Abrahmsen Lars B. SVP, Chief Scientific Officer | Option exercise · Stock Option (right to Buy) | −50,000 | 30,587 | ||
| 2021-10-01 | Korbel Gregory Alan SVP, Chief Business Officer | Option exercise | +27,500 | $0.92 | $25K | 44,667 |
| 2021-10-01 | Korbel Gregory Alan SVP, Chief Business Officer | Sale | −27,500 | $4.89 | $134K | 17,167 |
Page 9 of 10 · 197 trades